Navigation Links
Rigel Announces First Quarter 2013 Financial Results
Date:5/7/2013

evelopment programs, including the timing of commencement and completion of ongoing clinical trials and results thereof, the timing and design of its future clinical trials and potential milestones and regulatory filings associated with Rigel's product candidates, Rigel's corporate collaborations, and revenues that may be received from collaborations and the timing of those potential payments. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "expect," "will," "may," "aim," "believe," "plan,"  "potential," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, the uncertain timing and success of preclinical studies and clinical trials and the potential problems that may arise in the clinical development, the uncertain and time-consuming regulatory filing and approval process, the availability of resources to develop Rigel's product candidates, the uncertain therapeutic and commercial value of fostamatinib, market competition, risks associated with Rigel's dependence on corporate collaborations and partnerships, including risks that if conflicts arise between Rigel's and its corporate partners or advisors, the clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated, risks associated with Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's reports with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012. Rigel does not undertake
'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
5. Rigel to Present at UBS Global Life Sciences Conference
6. Rigel Announces Third Quarter 2012 Financial Results
7. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
8. Rigel to Present at BIO CEO & Investor Conference
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
11. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 The International ... of myeloma patients while working toward prevention and a ... (D-NY) for introducing a federal resolution (H. Res. 174) ... 2015 as "National Multiple Myeloma Awareness Month." ... myeloma worldwide, and more than 110,000 new cases are ...
(Date:3/27/2015)... March 27, 2015 RnRMarketResearch.com ... therapeutic market research report of 52 pages with ... business intelligence library. The report "Visceral ... the therapeutic development for Visceral Pain, complete with ... drug target, mechanism of action (MoA), route of ...
(Date:3/26/2015)... 26, 2015  The Burzynski Research Institute, Inc. (BRI) ... conducted by the Department of Surgery at Kurume ... have been published. The study, a randomized ... infusion as post-operative adjuvant therapy with and without ... liver. A total of 65 ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of its ... and coolest applications on the market for iOS, Android, ... technology expert, conducted the app review and shared with ... with knights, nature, and peasants. , The first ... Eurogamer. The popularity of these games grew over the ...
(Date:3/28/2015)... York, New York (PRWEB) March 28, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. Bard, ... litigation underway in U.S. District Court, Southern District ... S. Grand, is serving on the Plaintiffs’ Steering ... 24th, the Court has granted certain defendants named ...
(Date:3/28/2015)... India Network visitor health insurance ... to all visitors who purchase the plan before arrival ... encouraged to purchase the insurance program as soon as ... coverage for pre-existing medical conditions. Parents and grandparents traveling ... conditions with serious consequences to their health. Many visitors ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... correlate with a history of shoulder and elbow injuries, according ... for Sports Medicine’s ( AOSSM ) Specialty Day. , “Our ... associated with a 20% increase in likelihood of a history ... is associated with a 12% increase likelihood of a history ...
(Date:3/28/2015)... 2015 Delaying rotator cuff surgery on ... to research presented today at the American Orthopaedic Society ... “Our study compared results for 170 patients who received ... glenohumeral joint capsule release procedure to relieve stiffness at ... lead author from St. George Hospital in Sydney, Australia. ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2
... must plan for the possibility that crucial infrastructure such ... of an //influenza pandemic, biosecurity and health specialists have ... of Australia. ,In a special influenza ... the National Centre for Immunisation Research and Surveillance of ...
... need better resources and support to care for patients ... // ,In an editorial for the ... practice and family health specialists have outlined new international ... which partner violence is occurring. ,Over ...
... recent survey conducted in Australia shows that majority of Australians ... of cancers affecting the lymphatic system is termed as lymphomas. ... to sieve out bacteria and aids to fight ... cancer that afflicts more women than cervical or ovarian cancer ...
... research from UT Southwester Medical Center, children who were treated ... for strokes later in life. // ,In addition, childhood ... to kill the cancer showed even greater risk of stroke ... the Nov. 20 issue of the Journal of Clinical Oncology ...
... Traditionally, mothers across the world vehemently oppose wastage of ... third world countries have children who are starving. //However ... reports about Canadians who take the effort to make ... food on their bodies as well. Trendy and fashionable ...
... Dengue Vaccine Initiative (PDVI), a program of the International ... today their partnership to help develop and make a ... Dengue fever, the second most widespread tropical disease after ... which over 2 billion people are exposed and which ...
Cached Medicine News:Health News:Pandemic Planning for Hospitals 2Health News:Tackling Violence in Families 2Health News:Childhood Survivors Of Brain Tumors More At Risk For Strokes Later In Life 2Health News:Childhood Survivors Of Brain Tumors More At Risk For Strokes Later In Life 3Health News:Tasty Cosmetic Recipes to flavor your day 2Health News:Pediatric Dengue Vaccine Initiative and Hawaii Biotech Partner Against Dengue Fever 2
... The Surgifoam* absorbable gelatin sponge, ... porcine gelatin absorbable sponge intended for ... bleeding surface. The sponge is off-white ... and speed to hemostasis, highly favorable ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
Practice-oriented ophthalmic laser systems for photodisruption....
Medicine Products: